Newsroom

BOCA RATON, Fla.--(BUSINESS WIRE)--SBA Communications Corporation (NASDAQ: SBAC) (“SBA”) announces that Marc Montagner, Chief Financial Officer, is scheduled to speak at Citi’s 2026 Global TMT Conference, Wednesday, September 9, 2026, at 10:10 AM ET. The conference will be held at The New York Hilton Midtown in New York. Marc Montagner is also scheduled to speak at the BofA Securities 2026 Media, Communications and Entertainment Conference, Thursday, September 10, 2026, at 8:50 AM ET. This conf...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 25.08.2026 CPQ IE00BFD2H405 6,325,002.00 USD 421,385,344.34   66.622  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 25.08.2026 FDNU IE00BG0SSC32 1,250,002.00 USD  49,598,436.74   39.679  ...

ATLANTA--(BUSINESS WIRE)--The Georgia Council on Economic Education today announced its support of the Advanced Placement (AP) Business with Personal Finance course, calling on Georgia education leaders to promote and adopt it as an option to provide high-quality financial literacy education. "Every Georgia student deserves to graduate with the financial knowledge and skills to navigate adult life successfully," said Mike Raymer, Executive Director of the Georgia Council on Economic Education....

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg. Diana F. Clarke, Pharm.D., As...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Cybersecurity UCITS ETF 25.08.2026 NQCYBREN IE00BF16M727 27,485,554.00 USD 1,570,213,526.90   57.129  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 25.08.2026 FBTU.LN IE00BL0L0H60  500,002.00 USD  16,683,356.32   33.367  ...

LOS ANGELES--(BUSINESS WIRE)--AVEX Investors Have Opportunity to Lead AEVEX Corp. Securities Fraud Lawsuit with SBS Law...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled “Neoadjuvant botensilimab/balstilimab for localized mismatch r...